Top

Published in:

01-12-2014 | Meeting Report

Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist

Authors: Rodolfo Montironi, Elizabeth H. Hammond, Daniel W. Lin, John L. Gore, John R. Srigley, Hema Samaratunga, Lars Egevad, Mark A. Rubin, John Nacey, Laurence Klotz, Howard Sandler, Anthony L. Zietman, Stuart Holden, Peter A. Humphrey, Andrew J. Evans, Brett Delahunt, Jesse K. McKenney, Daniel Berney, Thomas M. Wheeler, Arul Chinnaiyan, Lawrence True, Beatrice Knudsen, Jonathan I. Epstein, Mahul B. Amin

Published in: Virchows Archiv | Issue 6/2014

Abstract

Active surveillance (AS) is an important management option for men with low-risk, clinically localized prostate cancer. The clinical parameters for patient selection and definition of progression for AS protocols are evolving as data from several large cohorts matures. Vital to this process is the critical role pathologic parameters play in identifying appropriate candidates for AS. These findings need to be reproducible and consistently reported by surgical pathologists. This report highlights the importance of accurate pathology reporting as a critical component of these protocols.

Available only for authorised users

Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR, Investigators CPSURE (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401PubMedCrossRef

Albertsen PC, Hanley JA, Fine J (2005) 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101PubMedCrossRef

Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123PubMedCentralPubMedCrossRef

Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300–4305PubMedCentralPubMedCrossRef

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981–990PubMedCrossRef

Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719PubMedCrossRef

McGregor M, Hanley JA, Boivin JF, McLean RG (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159:1368–1372PubMedCentralPubMed

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O’Leary M, Walker-Corkery E, Yao SL (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209PubMedCentralPubMedCrossRef

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef

10.

Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131PubMedCrossRef

11.

Network NCC (2010) NCCN clinical practice guidelines in oncology: prostate cancer. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

12.

Dall’Era MA, Cooperberg MR, Chan JM, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112:1650–1659PubMedCrossRef

13.

Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R (2012) Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 18:5471–5478PubMedCentralPubMedCrossRef

14.

Ganz PABJ, Burke W, Col NF, Corso PS, Dodson E, Hammond ME, Kogan BA, Lynch CF, Newcomer L, Seifter EJ, Tooze JA, Viswanath K, Wessells H (2011) National institutes of health state-of-the-science conference statement: role of active surveillance in the management of men with localized prostate cancer. NIH Consens State Sci Statement 28:1–27

15.

Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, et al. (2014) The critical role of the pathologist in determining eligibility for active surveillance as a management options in patients with prostate cancer: consensus statement with recommendations supported by the college of american pathologist, international society of urologic pathologist, association of directors of anatomic and surgical pathology, the New Zealand society of pathologists and the prostate cancer foundation. Arch Pathol Lab Med

16.

Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63:597–603PubMedCrossRef

17.

Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRef

18.

Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185–2190PubMedCrossRef

19.

Montironi R, Lopez-Beltran A, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L (2014) Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. Anal Quant Cytol Histol 36:61–70

20.

Montironi R, Scarpelli M, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montorsi F (2012) Extent of cancer of less than 50 % in any prostate needle biopsy core: how many millimeters are there? Eur Urol 61:751–756PubMedCrossRef

21.

Brimo F, Vollmer RT, Corcos J, Kotar K, Begin RL, Humphrey PA, Bismar TA (2008) Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 53:177–183PubMedCrossRef

22.

Karram S, Trock BJ, Netto GJ, Epstein JI (2011) Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 35:1351–1355PubMedCrossRef

23.

Schultz L, Maluf CE, da Silva RC, Falashi Rde H, da Costa MV, Schultz MI (2013) Discontinuous foci of cancer in a single core of prostatic biopsy: when it occurs and performance of quantification methods in a private-practice setting. Am J Surg Pathol 37:1831–1836PubMedCrossRef

24.

Epstein JI (2010) An update of the Gleason grading system. J Urol 183:433–440PubMedCrossRef

25.

Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446–1452PubMedCentralPubMedCrossRef

Title: Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist
Authors: Rodolfo Montironi
Elizabeth H. Hammond
Daniel W. Lin
John L. Gore
John R. Srigley
Hema Samaratunga
Lars Egevad
Mark A. Rubin
John Nacey
Laurence Klotz
Howard Sandler
Anthony L. Zietman
Stuart Holden
Peter A. Humphrey
Andrew J. Evans
Brett Delahunt
Jesse K. McKenney
Daniel Berney
Thomas M. Wheeler
Arul Chinnaiyan
Lawrence True
Beatrice Knudsen
Jonathan I. Epstein
Mahul B. Amin
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 6/2014
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1668-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Incidental prostate cancer prevalence at radical cystoprostatectomy—importance of the histopathological work-up

Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer

Total burden of intraplaque hemorrhage in coronary arteries relates to the use of coumarin-type anticoagulants but not platelet aggregation inhibitors

SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma

Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens

Evaluation of clinico-pathological features and Helicobacter pylori infection in gastric inflammatory fibroid polyps